Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metamelfalan SCHEMBL30781236 | 1.00 | CYP3A4 (0.70) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| Metamelfalan SCHEMBL6842568 | 1.00 | CYP3A4 (0.70) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| Metamelfalan SCHEMBL2015275 | 1.00 | CYP3A4 (0.70) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| Melphalan SCHEMBL4984726 | 0.84 | HIF1A (0.91) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL18427979 | 0.84 | IDO1 (0.57) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL19714971 | 0.84 | IDO1 (0.57) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL18427948 | 0.84 | IDO1 (0.57) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL6843476 | 0.83 | SMN1; SMN2 (0.53) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL2778981 | 0.83 | NOS3 (0.56) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 | |
| SCHEMBL2778977 | 0.83 | NOS3 (0.56) | CYP3A4ALOX15HIF1APTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2011078782-A1 | A COMPOSITION COMPRISING OF MELPHALAN DERIVATIVES AND GEMCITABINE OR ETOPOSIDE USEFUL IN THE TREATMENT OF CANCER | ONCOPEPTIDES AB (SE) | 2011-06-30 | — | — | WO | disclosed |
| EP-1290011-B1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2010-02-24 | — | — | EP | disclosed |
| US-6992207-B2 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES AB (SE) | 2006-01-31 | — | — | US | disclosed |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES INNOVATION AB (SE) | 2004-05-20 | — | — | US | disclosed |
| US-5523084-A | ANTICARCINOGENIC AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-06-04 | — | — | US | disclosed |
| US-5407672-A | Reduces plasma level of large neutral amino acids to allow for increased melphalan transport into tumors | CORNELL RESEARCH FOUNDATION, INC. (US) | 1995-04-18 | — | — | US | disclosed |
| WO-1994023741-A1 | ENHANCING THE ANTI-TUMOR EFFECT OF MELPHALAN WITH L-AMINO ACID OXIDASE | CORNELL RESEARCH FOUNDATION, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | MCL1, LNPEP, MYADM | CYP3A4 4312/4885ALOX15 4196/4885HIF1A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.